Novel Drug Review of Select
​
Neurologic Drugs Approved in 2019
Michelle Boysel
Abstract
Each year, the Food and Drug Administration (FDA) releases a comprehensive list of all novel drugs approved throughout the year. The FDA’s Center for Drug Evaluation and Research strives to approve new drugs to fill the gaps in healthcare of unmet needs of patients. This article focuses on select novel drugs approved in 2019, specifically for neurologic conditions. Drugs included are Cyplyta, a second-generation antipsychotic used in the maintenance of schizophrenia; Ubrelvy, a CGRP antagonist used for acute migraine attacks; Zulresso, the first drug treatment indicated for postpartum depression; and Wakix, the first noncontrolled treatment for excessive daytime sleepiness in narcoleptic patients.
Full Text
neuro_drugs_2019.pdf
File Size: 283 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH